SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 14
|
records per page:
next > | last >>
|
THEMED DISCUSSION: KSHV VIROLOGY AND PATHOGENESIS
THEMED DISCUSSION LEADER
Blossom Damania
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
THEMED DISCUSSION: KSHV VIROLOGY AND PATHOGENESIS
PRIMARY ROLE OF KSHV IN PATHOGENESIS OF ENDEMIC AND EPIDEMIC KAPOSI SARCOMA
(ABSTRACT
270)
Salum Juma Lidenge
University of Nebraska-Lincoln, Lincoln, NE, USA
THEMED DISCUSSION: KSHV VIROLOGY AND PATHOGENESIS
METABOLIC ABNORMALITIES IN CD8 T CELLS FROM HIV+ INDIVIDUALS WITH KAPOSI SARCOMA
(ABSTRACT
271)
Genevieve Tyndale Clutton
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
THEMED DISCUSSION: KSHV VIROLOGY AND PATHOGENESIS
SINGLE CELL EVALUATION OF KAPOSI SARCOMA TUMORS REVEALS COMPLEX IMMUNE INFILTRATE
(ABSTRACT
272)
Warren Phipps
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
THEMED DISCUSSION: KSHV VIROLOGY AND PATHOGENESIS
NEW VARIANT OF KAPOSI SARCOMA–ASSOCIATED HERPESVIRUS IN MEN WHO HAVE SEX WITH MEN
(ABSTRACT
273)
Aude Jary
AP–HP, Hôpitaux Universitaires Pitié Salpêtrière, Paris, France
THEMED DISCUSSION: KSHV VIROLOGY AND PATHOGENESIS
THEMED DISCUSSION: LETS CHECK IN! NEW TOOLS FOR MONITORING ART AND PrEP ADHERENCE
THEMED DISCUSSION LEADER
Rodolphe Garraffo
Université de Nice-Sophia-Antipolis, Hôpital Pasteur, CHU de Nice, Nice, France
THEMED DISCUSSION: LETS CHECK IN! NEW TOOLS FOR MONITORING ART AND PrEP ADHERENCE
PI DRUG-LEVEL TESTING AS A SCREENING TOOL FOR DRUG RESISTANCE IN 2ND-LINE ART FAILURE
(ABSTRACT
461)
Lucas Etienne Hermans
University Medical Center Utrecht, Johannesburg, South Africa
THEMED DISCUSSION: LETS CHECK IN! NEW TOOLS FOR MONITORING ART AND PrEP ADHERENCE
PLASMA EFV AND TFV VS DRIED BLOOD SPOT TFV-DP TO PREDICT VIRAL SUPPRESSION IN WOMEN
(ABSTRACT
462)
Tamsin Kate Phillips
University of Cape Town, Cape Town, South Africa
THEMED DISCUSSION: LETS CHECK IN! NEW TOOLS FOR MONITORING ART AND PrEP ADHERENCE
TENOFOVIR DIPHOSPHATE IN DRIED BLOOD SPOTS FOLLOWING ESCALATING TAF/FTC DOSING
(ABSTRACT
463)
Jenna Yager
University of Colorado, Aurora, CO, USA
THEMED DISCUSSION: LETS CHECK IN! NEW TOOLS FOR MONITORING ART AND PrEP ADHERENCE
VALIDATION OF A URINE TFV IMMUNOASSAY FOR REAL-TIME PREP AND ART ADHERENCE TESTING
(ABSTRACT
464)
Monica Gandhi
University of California San Francisco, San Francisco, CA, USA
THEMED DISCUSSION: LETS CHECK IN! NEW TOOLS FOR MONITORING ART AND PrEP ADHERENCE
URINE FTC AND TFV CONCENTRATIONS AS POTENTIAL BIOMARKERS FOR ARV ADHERENCE
(ABSTRACT
465)
Richard Haaland
Centers for Disease Control and Prevention, Laboratory Branch, Division of HIV/AIDS Prevention, Atlanta, GA, USA
THEMED DISCUSSION: LETS CHECK IN! NEW TOOLS FOR MONITORING ART AND PrEP ADHERENCE
THEMED DISCUSSION: STRUCTURE AND LOCATION OF PROVIRUSES ON ART
THEMED DISCUSSION LEADER
Sarah Palmer
The Westmead Institute for Medical Research, Westmead, NSW, Australia
THEMED DISCUSSION: STRUCTURE AND LOCATION OF PROVIRUSES ON ART
A METHOD TO DETERMINE BOTH THE INTEGRATION SITES AND SEQUENCES OF HIV-1 PROVIRUSES
(ABSTRACT
338)
Sean Patro
National Cancer Institute, Frederick, MD, USA
THEMED DISCUSSION: STRUCTURE AND LOCATION OF PROVIRUSES ON ART
DISTINCT CHROMOSOMAL POSITIONS OF INTACT HIV-1 PROVIRUSES
(ABSTRACT
339)
Kevin Einkauf
Brigham and Women's Hospital, Cambridge, MA, USA
THEMED DISCUSSION: STRUCTURE AND LOCATION OF PROVIRUSES ON ART
RELATIONSHIP BETWEEN INTACT HIV-1 PROVIRUSES AND PLASMA REBOUND VIRUSES
(ABSTRACT
340)
Ching-Lan Lu
The Rockefeller University, New York, NY, USA
THEMED DISCUSSION: STRUCTURE AND LOCATION OF PROVIRUSES ON ART
LANDSCAPE OF HIV-1 INTEGRATION SITES IN LYMPHOID TISSUE FROM ART-TREATED INDIVIDUALS
(ABSTRACT
341)
Vincent H. Wu
University of Pennsylvania, Philadelphia, PA, USA
THEMED DISCUSSION: STRUCTURE AND LOCATION OF PROVIRUSES ON ART
GENETIC AND AGE DISTRIBUTION OF LATENT HIV SEQUENCES IN CD4+ T-CELL SUBSETS
(ABSTRACT
342)
Zabrina Brumme
Simon Fraser University, Burnaby, British Columbia, Canada
THEMED DISCUSSION: STRUCTURE AND LOCATION OF PROVIRUSES ON ART
THEMED DISCUSSION: THE MASKED MARVELS YOU DON'T WANT TO MEET: SYPHILIS AND LGV
THEMED DISCUSSION LEADER
Khalil G Ghanem
Johns Hopkins University, Baltimore, MD, USA
THEMED DISCUSSION: THE MASKED MARVELS YOU DON'T WANT TO MEET: SYPHILIS AND LGV
EFFECTIVE TREATMENT OF LYMPHOGRANULOMA PROCTITIS WITH EXTENDED AZITHROMYCIN REGIMEN
(ABSTRACT
1011)
José L Blanco
Hospital Clinic, Barcelona, Spain
THEMED DISCUSSION: THE MASKED MARVELS YOU DON'T WANT TO MEET: SYPHILIS AND LGV
ADHERENCE OF HEALTH CARE PROVIDERS TO CDC LUMBAR-PUNCTURE CRITERIA AMONG SYPHILIS/HIV
(ABSTRACT
1012)
Barbara Labella Henriques
Universidad de São Paulo, São Paulo, Brazil
THEMED DISCUSSION: THE MASKED MARVELS YOU DON'T WANT TO MEET: SYPHILIS AND LGV
HEARING LOSS IN UNSELECTED INDIVIDUALS WITH SYPHILIS
(ABSTRACT
1013)
Meena Ramchandani
University of Washington, Seattle, WA, USA
THEMED DISCUSSION: THE MASKED MARVELS YOU DON'T WANT TO MEET: SYPHILIS AND LGV
COGNITIVE IMPAIRMENT IN INDIVIDUALS WITH SYPHILIS
(ABSTRACT
1014)
Kevin Robertson
University of North Carolina - Chapel Hill, Chapel Hill, NC, USA
THEMED DISCUSSION: THE MASKED MARVELS YOU DON'T WANT TO MEET: SYPHILIS AND LGV
RESPONSE TO SYPHILIS TREATMENT: CDC GUIDELINES IN HIV-INFECTED ADULTS ON CART
(ABSTRACT
1015)
Melody Ren
University of Toronto, Toronto, Ontario, Canada
THEMED DISCUSSION: THE MASKED MARVELS YOU DON'T WANT TO MEET: SYPHILIS AND LGV
THEMED DISCUSSION: WOMEN WITH HIV: ARE OUTCOMES DIFFERENT?
THEMED DISCUSSION LEADER
Judith Aberg
Icahn School of Medicine at Mount Sinai, New York, NY, USA
THEMED DISCUSSION: WOMEN WITH HIV: ARE OUTCOMES DIFFERENT?
IMPORTANT SEX DIFFERENCES IN OUTCOMES FOR INDIVIDUALS PRESENTING FOR THIRD-LINE ART
(ABSTRACT
518)
Catherine Godfrey
National Institute of Health, Bethesda, MD, USA
THEMED DISCUSSION: WOMEN WITH HIV: ARE OUTCOMES DIFFERENT?
DEPRESSION IS A STRONGER PREDICTOR OF EXECUTIVE DYSFUNCTION IN HIV+ WOMEN THAN MEN
(ABSTRACT
516)
Leah H Rubin
Johns Hopkins University, Baltimore, MD, USA
THEMED DISCUSSION: WOMEN WITH HIV: ARE OUTCOMES DIFFERENT?
GENDER AND COINFECTIONS CONTRIBUTE TO IMMUNE ACTIVATION IN TREATED HIV INFECTION
(ABSTRACT
517)
Hendrik Streeck
Institute for HIV Research, Essen, Germany
THEMED DISCUSSION: WOMEN WITH HIV: ARE OUTCOMES DIFFERENT?
TENOFOVIR ALAFENAMIDE VS TENOFOVIR DF IN WOMEN: POOLED ANALYSIS OF 7 CLINICAL TRIALS
(ABSTRACT
519)
Melanie Thompson
AIDS Research Consortium of Atlanta, Atlanta, GA, USA
THEMED DISCUSSION: WOMEN WITH HIV: ARE OUTCOMES DIFFERENT?
EFFECT OF ANTIRETROVIRAL THERAPY AND IMMUNE RECONSTITUTION ON VAGINAL MICROBIOME
(ABSTRACT
520)
Zoe Packman
Johns Hopkins University, Baltimore, MD, USA
THEMED DISCUSSION: WOMEN WITH HIV: ARE OUTCOMES DIFFERENT?
THEMED DISCUSSION: EARLY EVENTS
THEMED DISCUSSION LEADER
Michael Emerman
Fred Hutchinson Cancer Research Center, Seattle, WA, USA
THEMED DISCUSSION: EARLY EVENTS
ENTRY KINETICS OF GLOBALLY REPRESENTATIVE AND VERTICALLY TRANSMITTED HIV ENVELOPES
(ABSTRACT
166)
Nicholas E. Webb
University of California Los Angeles, Los Angeles, CA, USA
THEMED DISCUSSION: EARLY EVENTS
CD4-DEPENDENT MODULATION OF HIV-1 ENTRY BY LY6E
(ABSTRACT
167)
Shan-Lu Liu
The Ohio State University, Columbus, OH, USA
THEMED DISCUSSION: EARLY EVENTS
ELUCIDATING MECHANISMS BY WHICH MUTATIONS IN ENV CONTRIBUTE TO HIV-1 DRUG RESISTANCE
(ABSTRACT
168)
Rachel Van Duyne
National Cancer Institute, Frederick, MD, USA
THEMED DISCUSSION: EARLY EVENTS
NONRANDOM GENERATION OF DELETIONS WITHIN HIV PROVIRAL SEQUENCES IN VIVO
(ABSTRACT
169)
Bonnie Hiener
The Westmead Institute for Medical Research, Westmead, Australia
THEMED DISCUSSION: EARLY EVENTS
HOST FACTORS INFLUENCE SIV AND HIV-1 INFECTION AND SENSITIVITY TO CAPSID INHIBITORS
(ABSTRACT
170)
Carsten Münk
Heinrich-Heine-University Hospital, Düsseldorf, Germany
THEMED DISCUSSION: EARLY EVENTS
THEMED DISCUSSION: INSIGHT FROM ANALYTICAL TREATMENT INTERRUPTIONS
THEMED DISCUSSION LEADER
John Frater
University of Oxford, Oxford, United Kingdom
THEMED DISCUSSION: INSIGHT FROM ANALYTICAL TREATMENT INTERRUPTIONS
ANALYTICAL TREATMENT INTERRUPTION (ATI) IN PATIENTS WITH VERY SMALL HIV RESERVOIR
(ABSTRACT
389)
Eric Florence
Institute of Tropical Medicine, Antwerpen, Antwerpen, Belgium
THEMED DISCUSSION: INSIGHT FROM ANALYTICAL TREATMENT INTERRUPTIONS
N-803 INDUCES ROBUST SIV REACTIVATION IN ART-TREATED CD8-DEPLETED MACAQUES
(ABSTRACT
390)
Julia Bergild McBrien
Yerkes National Primate Research Center, Atlanta, GA, USA
THEMED DISCUSSION: INSIGHT FROM ANALYTICAL TREATMENT INTERRUPTIONS
REBOUND OF HIV-1 IN CEREBROSPINAL FLUID AFTER TREATMENT INTERRUPTION
(ABSTRACT
391)
Richard W Price
University of California San Francisco, San Fransisco, CA, USA
THEMED DISCUSSION: INSIGHT FROM ANALYTICAL TREATMENT INTERRUPTIONS
COMPARTMENTALIZED HIV REBOUND IN THE MALE GENITAL TRACT AFTER ART INTERRUPTION
(ABSTRACT
392)
Sara Gianella
University of California San Diego, La Jolla, CA, USA
THEMED DISCUSSION: INSIGHT FROM ANALYTICAL TREATMENT INTERRUPTIONS
SEEKING SUPPRESSION IN HAVARTI: VIREMIA & T CELLS AFTER VEDOLIZUMAB & ATI IN HIV/ART
(ABSTRACT
393)
Michaeline McGuinty
University of Ottawa, Ottawa, Canada
THEMED DISCUSSION: INSIGHT FROM ANALYTICAL TREATMENT INTERRUPTIONS
THEMED DISCUSSION: NOVEL PUBLIC HEALTH: CLUSTERS, CONTRASTS AND PHYLOGENETICS
THEMED DISCUSSION LEADER
Frank Tanser
Africa Health Research Institute, Durban, South Africa
THEMED DISCUSSION: NOVEL PUBLIC HEALTH: CLUSTERS, CONTRASTS AND PHYLOGENETICS
INCIDENT INFECTION IN HIGH-PRIORITY HIV MOLECULAR TRANSMISSION CLUSTERS
(ABSTRACT
856)
Joel O. Wertheim
University of California, San Diego, San Diego, CA, USA
|
<< first | < prev
page:
of 14
|
records per page:
next > | last >>
|
